Shutterstock Retreats on Q4 Numbers
Shutterstock, Inc. (NYSE: SSTK) saw its shares fall Tuesday. The company which purports to be a leading global creative platform offering high-quality creative content for transformative brands, digital media and marketing companies, today announced financial results for the full year and fourth quarter ended December 31, 2024.Full-year revenues were $935.3 million compared to $874.6 million. Net income was $35.9 million compared to $110.3 million. Net income per diluted common share was $1.01 compared to $3.04.In the year’s last quarter, revenues were $250.3 million compared to $217.2 million. Net loss was $1.4 million compared to $1.0 million. Net loss per diluted common share was $0.04 compared to $0.03.Commenting on the company's performance, CEO Paul Hennessy said, "We are proud that Shutterstock achieved record revenues and Adjusted EBITDA in 2024. Our Content business grew on a year over year basis and each component of our Data, Distribution and Services business grew double digits or greater on a year over year basis and we expect continued growth across both of these offerings in 2025."During the three months ended December 31, 2024, the Company declared and paid a cash dividend of $0.30 per common share or $10.4 million.On January 27, 2025, the Board of Directors declared a dividend of $0.33 per share of outstanding common stock, payable on March 20, 2025 to stockholders of record at the close of business on March 6, 2025.SSTK shares stumbled $1.51, or 6.2%, to $23.00.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


